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Abstract: Background: The beneficial impact of mesenchymal stem cells (MSC) on both acute and
chronic liver diseases has been confirmed, although the molecular mechanisms behind it remain
elusive. We aim to identify factors secreted by undifferentiated and hepatocytic differentiated MSC
in vitro in order to delineate liver repair pathways potentially targeted by MSC. Methods: Secreted
factors were determined by protein arrays and related pathways identified by biomathematical
analyses. Results: MSC from adipose tissue and bone marrow expressed a similar pattern
of surface markers. After hepatocytic differentiation, CD54 (intercellular adhesion molecule 1,
ICAM-1) increased and CD166 (activated leukocyte cell adhesion molecule, ALCAM) decreased.
MSC secreted different factors before and after differentiation. These comprised cytokines involved
in innate immunity and growth factors regulating liver regeneration. Pathway analysis revealed
cytokine-cytokine receptor interactions, chemokine signalling pathways, the complement and
coagulation cascades as well as the Januskinase-signal transducers and activators of transcription
(JAK-STAT) and nucleotide-binding oligomerization domain-like receptor (NOD-like receptor)
signalling pathways as relevant networks. Relationships to transforming growth factor β (TGF-β)
and hypoxia-inducible factor 1-α (HIF1-α) signalling seemed also relevant. Conclusion: MSC secreted
proteins, which differed depending on cell source and degree of differentiation. The factors might
address inflammatory and growth factor pathways as well as chemo-attraction and innate immunity.
Since these are prone to dysregulation in most liver diseases, MSC release hepatotropic factors,
potentially supporting liver regeneration.
Keywords: mesenchymal stem cells; secretome; cytokines; chemokines; liver regeneration;
hepatocytic differentiation; bone marrow; adipose tissue
1. Introduction
The biological features of mesenchymal stem cells (MSC) make them feasible candidates for
cellular therapy for a variety of diseases, e.g., acute kidney injury, brain repair after stroke, colitis [1–6],
and acute and chronic liver diseases [7–14]. Depending on the therapeutic goal, MSC might be used
as undifferentiated cells to provide regenerative support by paracrine actions or after hepatocytic
differentiation to provide metabolic capacity, or to bridge the patient to liver transplantation [15].
Currently, a series of clinical phase-I trials using MSC as therapy option to treat liver diseases
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are in progress [16,17], albeit the molecular mechanisms of the stem cells’ impact remain mostly
elusive. At low rates, transplanted MSC engrafted into the host liver and adopted the full hepatocyte
phenotype [18,19]. In recent times, however, it has been shown that the beneficial effect of MSC
is often mediated by transient, paracrine mechanisms comprising the secretion of soluble factors
by the MSC without requiring hepatic engraftment [7,20–24]. If this is the principle of action, then
the question arises whether MSC derived from different tissue sources display the same paracrine
pattern of secreted factors. In particular, differences in cytokines, chemokines and growth factors
involved in hepatocyte differentiation and growth would of course have significant therapeutic impact
on liver repair and regeneration. Since cytokines and chemokines mediate both inflammatory and
anti-inflammatory responses, it is from a clinical point of view relevant to know, whether a given
disease imprints the panel of proteins secreted by the MSC, which might then behave differently
under different disease conditions [25–27]. In the liver, paracrine and also endocrine factors play
an important role in cell and tissue homeostasis. For example, the cytokine interleukin 6 (IL-6)
secreted by Kupffer cells is the prominent cytokine initiating the acute phase reaction as the first line
of defence against trauma, tissue damage or neoplastic growth, and together with tumour necrosis
factor α (TNFα) is the priming factor initiating liver regeneration after damage like for example
after partial hepatectomy [28,29]. A row of MSC-derived factors with pleiotropic actions might also
potentially foster liver regeneration via multiple pathways like TGFα promoting vascularization
and mitogenesis [29,30], or angiogenic factors like vascular endothelial growth factor (VEGF) and
angiopoietins 1 and 2 [30]. Conversely, thrombospondin-1 induces apoptosis and antagonizes VEGF by
activating the c-Jun N-terminal kinase (JNK) pathway via binding to the scavenger receptor CD36 [31],
thus contributing to tissue remodelling during liver regeneration. Furthermore, morphogenic pathways
in the liver are impacted by MSC-borne factors like the Wnt pathway via its inhibitor Dickkopf-1,
which is crucial for metabolic imprinting of hepatocytes along the sinusoids, and thus for functional
homeostasis during tissue regeneration [32]. Besides their capacity to support tissue homeostasis
and function, MSC-derived molecules attenuate inflammatory diseases, like TGF-β1 alleviating
experimental colitis [6], or the anti-inflammatory cytokines IL-4 and IL-10 inducing polarisation
of macrophages into the ”non-inflammatory” M2 phenotype, thus attenuating inflammation in
non-alcoholic steatohepatitis (NASH) [25]. Eventually, TGF-β, which does not only display beneficial
but also deleterious actions in the liver like initiation of fibrosis by the activation of hepatic stellate
cells, is involved in multiple pathways comprising the JAK-STAT, JNK and mitogen-activated protein
kinases (MAPK) pathways [33,34] and their crosstalk with cyto- and chemokine pathways mediated
by fibroblast growth factors (FGFs) [35], CC chemokine ligands (CCLs) [36], interleukines (ILs) [37]
and brain-derived neurotrophic factor (BDNF) [38]. Therefore, it is of ultimate importance before
clinical application of MSC to characterise their potential mode of action in respect of their paracrine
response to a given liver disease. In this study, we identified cytokine profiles of undifferentiated
and hepatocytic differentiated MSC from different tissue origins with the aim to unravel signalling
pathways delineating their potential biological effects in vivo. We reasoned that MSC application might
target a widespread pattern of biological events in the liver, which may contribute to amelioration of
both acute and chronic liver diseases.
2. Results
2.1. Phenotypic Characteristics
As a typical feature of MSC, all subpopulations studied showed adherence to plastic culture
surfaces and a spindle-shaped morphology with the exception of visceral adipose tissue-derived MSC,
which contained in addition a contaminating subpopulation of untypically rounded cells. While bone
marrow and visceral as well as subcutaneous adipose tissue-derived MSC reached confluent growth
after about 8 days, mesenteric adipose tissue-derived MSC grew confluent after about 14 days, bona fide
indicating a lower proliferative capacity (Figure 1A).
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The expression of surface marker proteins was determined on all subpopulations of MSC. Yet, due
to the ease of availability, only hsubMSC and hbmMSC were further characterized in terms of surface
markers and functional features before and after hepatocytic differentiation. Undifferentiated human
MSC from either tissue under investigation expressed the mesenchymal surface marker panel
comprising CD13, CD29, CD44, CD90, CD105 and CD166 to nearly 100%. Fewer cells expressed
CD54 and CD71 and all were virtually negative for the hematopoietic markers CD14, CD34 and CD45.
Albeit significant, differences in the expression of CD13 and CD14 were marginal and thus negligible,
while the substantial difference in the expression of CD71 between hsubMSC and hbmMSC might be
of functional relevance (Figure 1B).
Comparing undifferentiated and hepatocytic differentiated MSC, the expression of CD54 increased
and that of CD166 decreased significantly on hsubMSC after differentiation. Although not significant,
hbmMSC showed the same trend. Notably, the expression of the hematopoietic marker CD34 increased
significantly up to 5.4% after differentiation of hsubMSC (Figure 1C).
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Figure 1. Phenotypic features of mesenchymal stem cells (MSC) from different tissue sources. In 
(A), the morphology of undifferentiated MSC derived from human bone marrow (hbm) and 
subcutaneous (hsub), visceral (hvis) and mesenteric (hmes) adipose tissue is shown (scale bar: 
100 µm). To reach near confluent growth (80%–90%), hbm-, hsub-, and hvis-MSC grew in about 
8 days, while hmesMSC needed more than 14 days of culture. (Scale bar: 100 µm); The 
mesenchymal and hematopoietic surface marker profile (B) of undifferentiated MSC derived 
from subcutaneous (hsub), visceral (hvis), mesenteric (hmes) adipose tissue and bone marrow 
(hbm) displayed only marginal quantitative differences; After hepatocytic differentiation (C) of 
hsubMSC and hbmMSC, the expression of CD54 increased while that of CD166 decreased 
significantly (* p < 0.05; mean values from three to five independent analyses using cells from 
different donors each). 
Figure 1. Phenotypic features of mesenchymal stem c lls (MSC) from different tissue sources. In (A),
the morphology of undifferentiate MSC derived from human bone marrow (hb ) and subcutaneous
(hsub), visceral (hvis) and mesent ic mes) a ipos tissue is shown (scale bar: 100 µm). To reach near
confluent growth (80%–90%), hbm-, hsub-, and hvis-MSC grew in about 8 days, while hmesMSC needed
more than 14 days of culture. (Scale bar: 100 µm); The mesenchymal and hematopoietic surface marker
profile (B) of undifferentiated MSC derived fro subcutaneous (hsub), visceral (hvis), mesenteric
(hmes) adipose tissue and bone marrow (hbm) displayed only marginal quantitative differences;
After hepatocytic differentiation (C) of hsubMSC and hbmMSC, the expression of CD54 increased
while that of CD166 decreased significantly (* p < 0.05; mean values from three to five independent
analyses using cells from different donors each).
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2.2. Identification of Hepatotropic Factors Secreted by Mesenchymal Stem Cells (MSC)
The analyses of the proteome profiler experiments were graphically summarised in the heatmap
shown in Figure 2. Quantitative and qualitative differences were obvious between hbmMSC and
hsubMSC, both undifferentiated and after hepatocytic differentiation.
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Figure 2. Heatmap of secretory protein abundance of undifferentiated (0 day) and differentiated  
(16 day) hbmMSC and hsubMSC. The heatmap was created by setting the maximal pixel intensity of 
the reference spots on the array arbitrarily to 100 (red colour), to which the abundance of all other 
analytes is relative. Minimal abundance (0) is encoded by white, mean abundance (50) by yellow 
colouring. Pixel densities shown were calculated as means from three independent experiments with 
MSC from different donors each. 
Figure 2. Heatmap of secretory protein abundance of undifferentiated (0 day) and differentiated
(16 day) hbmMSC and hsubMSC. The heatmap was created by setting the maximal pixel intensity of
the reference spots on the array arbitrarily to 100 (red colour), to which the abundance of all other
analytes is relative. Minimal abundance (0) is encoded by white, mean abundance (50) by yellow
colouring. Pixel densities shown were calculated as means from three independent experiments with
MSC from different donors each.
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Using an arbitrary classification, abundance of individual proteins was estimated at low, medium
and high secretion (epidermal growth factor (EGF) and hepatocyte growth factor (HGF) were not
considered, because both were components of the differentiation media). Protein abundance was
different in undifferentiated hbmMSC and hsubMSC. While in media of hbmMSC 40 proteins (18 low,
11 medium, 11 high) were verified, hsubMSC exhibited 31 secreted proteins (22 low, 1 medium, 8 high),
part of them overlapping in both as shown in the intersection presentation (Figure 3, top). Both MSC
populations secreted IL-17A, monocyte chemotactic protein 1 (MCP-1), Pentraxin-3, SerpinE1 and
Thrombospondin-1 in high abundance. IL-8 was highly abundant in supernatants of hsubMSC and
not found in supernatants of hbmMSC (Tables S1 and S2).
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Besides factors already secreted in high abundance in undifferentiated MSC, hepatocytic 
differentiation contributed a significant number of additional factors. Lists of individual proteins 
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and after differentiation, albeit overlapping to a certain extent (Figure 4). 
Figure 3. Graphical illustration of proteins secreted by undifferentiated (top) and differentiated
(bottom) hbmMSC (red) and hsubMSC (green). The pie charts represent the number of proteins
arbitrarily classified as low, medium and high secretion. The number of proteins not detected is shown
in grey. Proteins secreted both by hbmMSC and hsubMSC are shown as the intersection of proteins
secreted at low, medium and high abundance. Estimates were deduced from three independent
experiments using MSC from three different donors each.
In general, abundance of most proteins increased after hepatocytic differentiation (Figure 3,
bottom). 95 proteins (54 low, 10 medium, 31 high) were secreted by differentiated hbmMSC, and 70
(37 low, 8 mediu , 25 high) by differentiat d hsubMSC, 50 of which were found in supernatants of
both (intersections in Figure 3, bottom).
Besides factors already secreted n high abundance in undifferen iated MSC, hepatocytic
differentiation contributed a significant number of additional factors. Lists of individual proteins
secreted in low, medium or high abundance by diff entiated MSC are summarised in Tables S3 and S4.
In order to gain a comprehensive view of qualitative and semi-quantitative changes before and after
hepatocytic differentiation, graphical nets were designed, showing that secretory profiles of hsubMSC
and hbmMSC were qualitatively and quantitatively different from each other both, before and after
differentiation, albeit overlapping to a certain extent (Figure 4).
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Figure 4. iff r ti t ( l c lines) and dif erentiated
(orange lines) hb SC (left) and hsub SC (right) in lo (1), ediu (2) and high (3) ab n ance as
taken from results shown in Figure 3. Individual proteins are number d consecutively from 1 to 102 as
shown at the edg of the radii. A comprehensiv list of numbers and corresp nding proteins is given
in Table S5.
2.3. I e tificatio of ath ays and et orks f ected by Factors Secreted by SC
t ta e fro Fig re 4 ere subjected to analyses identifying path ays, ic i t be
targets of the proteins secreted by hsu MSC and hbmMSC before and after hepatocytic differentiation.
Pathways affected comprised immune d ase and cancer-r l te pathways as well as pathways
involved in cellular processes. As expected, pathways involved were mainly ident cal for both
hsubMSC and hbmMSC. Generally, the umber of proteins engaged in the pathways increased after
hepatocytic differentiation, corrobor ng that undifferenti ed MSC were equipped with a basic
profile of e ret ry proteins, tackling ach single pathway, up-regulated by hepatocytic differen iation
(F gu 5).
I order to achieve a higher resolution of putative biological net orks, ic i t be
si ific tl i t t e factors fo enric e in supernata ts of hsub S and hb S
ef re an after their hepatocytic differentiati , t e hig l ab a t rotei s as su arise i
S le e tary aterials ables S1–S4 ere subjected to net orks analyses i cl i t e re icti
f i teraction partners. The graphical su maries show in Figures 6 and 7 indicate
t at hepa ocyt c differentiati n of both cell populations increased the number of i t r cti
partners involved.
l or no significance, undifferentiated MSC might impact on pathways of both
the acquired and the innate i munity like cytokine-cytokine receptor i ti s yot
ncyclopedia of Gen s and Genomes (KEGG)) and the complement and coagulation casc de (hsa04610,
KEGG) as well as the NOD-like receptor signalling pathway (Table 1).
hese were highly significant after hepatocytic differentia on a d ew pathways emerged like the
c mokine (hsa04062, KEGG) and the JAK-ST T signallin pathway as ell th Toll-lik receptor
pathway (map04620, KEGG), all involved chemotactic and patter recognition innate immune
reactio s. In additio , growth promoting and a iogenic pathways were highlighted like bladder
cancer (hs 05219, KEGG), p53 signalling pathway (hsa04115, KEGG) and pathw ys in cancer (hsa05200,
KEGG) (Table 2).
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Figure 5. Pathway analysis of proteins secreted by hbmMSC (red) and hsubMSC (green) before
(light colours) and after (dark colours) hepatocytic differentiation. Pathways were identified using the
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (pathway identifiers
given in parentheses) and clustered into main disease- or cellular processes-related pathways (Y-axis).
The number of proteins involved in each single pathway is depicted on the X-axis. All pathways shown
were significant at the p < 0.05 level as calculated from three independent array analyses for each cell
type before and after differentiation.
Table 1. Pathway analysis by the David database of high abundance analytes secreted by
undifferentiated hbmMSC and hsubMSC (taken from Tables S1 and S2). Associated KEGG-pathways
with p-values of significance as well as analytes involved and “not found” are shown, respectively.
hbmMSC, Undifferentiated—High Abundance Analytes
Associated
KEGG-Pathway p-Value
Analytes Involved
(Entrez Gene ID)
Analytes Not Found
(Entrez Gene ID)
p53 signalling pathway 3.5 ˆ 10´3
IGFBP-3 (3486)
Thromposondin-1 (7057)
Serpin E1 (5054)
Angiogenin (283)
Chitinase 3-like 1 (1116)
MIF (4282)
Pentraxin-3 (5806)
Cytokine-cytokine
receptor interaction 4.7 ˆ 10
´2
MCP-1 (6347)
IL-17A (360 )
PDGF-AA (5154)
Complement and
coagulation cascade 9.1 ˆ 10
´2 Serpin E1 (5054)
Complement factor D (1675)
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Table 1. Cont.
hbmMSC, Undifferentiated-High Abundance Analytes
Associated
KEGG-Pathway p-Value
Analytes Involved
(Entrez Gene ID)
Analytes Not Found
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 2.4 ˆ 10´3
MCP-1 (6347)
ENA-78 (6374)
IL-17A (3605)
IL-8 (3576)
Dkk-1 (22,943)
Pentraxin-3 (5806)
Chemokine signalling
pathway 1.8 ˆ 10´2
MCP-1 (6347)
ENA-78 (6374)
IL-8 (3576)
Bladder cancer 4.9 ˆ 10´2 IL-8 (3576)Thromposondin-1 (7057)
NOD-like receptor
signalling pathway 7.1 ˆ 10´2
IL-8 (3576)
MCP-1 (6347)
p53 signalling pathway 7.8 ˆ 10´2 Thromposondin-1 (7057)Serpin E1 (5054)
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Fig re 6. Network of interacting cytokines (A) and additional 10 predicted potential interaction
art ers (B) of undifferentiated (upper panels) and hepatocytic differentiated (lower panels) hbmMSC.
Networks w re c eated by the STRING database using only protei s sec et d to high abundance as
summ rized in Tables S1 and S3. Connections betw en partners are shown in differe t colours; green:
activation, red: inhibition, blue: b nding, cyan: phenotype, violet: catalysis, pink: posttranslational
modification, b ack: reac yellow: expression. Bubble col ursare only for a b tter discrimination.
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Table 2. Pathway analysis by the David database of high abundance analytes secreted by hepatocytic
differentiated hbmMSC and hsubMSC (taken from Tables S3 and S4). Associated KEGG-pathways
with p-values of significance as well as analytes involved and “not found” are shown, respectively.
hbmMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Analytes Involved(Entrez Gene ID)
Analytes Not Found
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 2.4 ˆ 10
´11
MCP-1 (6347)
MCP-3 (3654)
MIP-3α (6364)
RANTES (6352)
GRO-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
M-CSF (1435)
GM-CSF (1437)
IL-17A (3605)
IL-6 (3569)
IL-8 (3576)
VEGF (7422)
Angiogenin (283)
Angiopoetin-1 (284)
EMMPRIN (682)
Chitinase 3-like 1 (1116)
Cystatin C (1471)
Dkk-1 (22,943)
Endoglin (2022)
FGF-19 (9965)
GDF-15 (9518)
IGFBP-2 (3485)
MIF (4282)
Pentraxin-3 (5806)
Resistin (56,729)
NOD-like receptor
signalling pathway 3.1 ˆ 10
´6
MCP-1 (6347)
RANTES (6352)
MCP-3 (6354)
GRO-α (2919)
IL-6 (3569)
IL-8 (3576)
Chemokine signalling
pathway 4.2 ˆ 10
´6
MCP-1 (6347)
MIP-3α (6364)
RANTES (6352)
MCP-3 (6354)
GRO-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-8 (3576)
Bladder cancer 1.2 ˆ 10´2
IL-8 (3576)
Thromposondin-1 (7057)
VEGF (7422)
p53 signalling pathway 2.9 ˆ 10´2
IGFBP-3 (3486)
Serpin E1 (5054)
Trombospondin 1 (7057)
Epithelial cell signalling in
Heliobacter pylori infection 2.9 ˆ 10
´2
RANTES (6352)
GRO-α (2919)
IL-8 (3576)
Complement and
coagulation cascade 2.9 ˆ 10
´2
uPAR (5329)
Serpin E1 (5054)
Complement factor D (1675)
Hematopoietic cell linage 4.4 ˆ 10´2
M-CSF (1435)
GM-CSF (1437)
IL-6 (3569)
Toll-like receptor
signalling pathway 5.9 ˆ 10
´2
RANTES (6352)
IL-6 (3569)
IL-8 (3576)
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Table 2. Cont.
hbmMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Analytes Involved(Entrez Gene ID)
Analytes Not Found
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 4.0 ˆ 10
´6
MCP-1 (6347)
GRO-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-17A (3605)
IL-8 (3576)
Leptin (3952)
VEGF (7422)
Angiogenin (283)
EMMPRIN (682)
Chitinase 3-like 1 (1116)
Cystatin C (1471)
Dkk-1 (22,943)
DPPIV (1803)
Endoglin (2022)
GDF-15 (9518)
IGFBP-2 (3485)
MIF (4282)
Pentraxin-3 (2806)
FGF-19 (9956)
Chemokine signalling
pathway 1.8 ˆ 10
´3
MCP-1 (6347)
GRO-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-8 (3576)
Bladder cancer 6.5 ˆ 10´2
IL-8 (3576)
Thromposondin-1 (7057)
VEGF (7422)
NOD-like receptor
signalling pathway 1.4 ˆ 10
´2
MCP-1 (6347)
GRO-α (2919)
IL-8 (3576)
p53 signalling pathway 1.7 ˆ 10´2
IGFBP-3 (3486)
Thromposondin-1 (7057)
Serpin E1 (5054)
Complement and
coagulation cascade 1.7 ˆ 10
´2
uPAR (5329)
Serpin E1 (5054)
Complement factor D (1675)
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Figure 7. et ork of interacting cytokines ( ) and additional 10 predicted potential interaction
partners (B) of undifferentiated (upper panels) and hepatocytic differentiated (lower panels) hsubMSC.
Networks were created by the STRING database using only proteins secreted at high abundance as
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activation, red: inhibiti , blue: binding, cyan: phe otype, violet: catalysis, pink: posttranslatio al
modification, black: reaction, yellow: expression. Bubble colours are only for a better discrimi ation.
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Taking into account prediction of 10 interaction partners, the identified pathways gained even
higher significance thereby substantiating either their physiological relevance, or additional pathways,
which were amended, featured growth and angiogenesis stimulation like glioma, melanoma or focal
adhesion (Tables 3 and 4).
Table 3. Pathway analysis by the David database of high abundance analytes secreted by
undifferentiated hbmMSC and hsubMSC and 10 potential interaction partners as predicted by the
STRING database (input of analytes as summarised in Tables S1 and S2). Associated KEGG-pathways
with p-values of significance as well as analytes involved are shown.
hbmMSC, Undifferentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Analytes Involved(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Complement and
coagulation cascades 3.8 ˆ 10
´5
SerpinE1 (5054)
Complement factor D (1675)
PLAT (5327)
PLG (5340)
PLAU (5328)
IGF1 (3479)
IGF2 (3481)
PLAU (5328)
IL-17RA (23,765)
CCR2 (1231)
PLAT (5327)
PLG (5340)
PRDM1 (639)
PDGFRA (5156)
CD47 (961)
p53 signalling pathway 9.3 ˆ 10´4
IGF1 (3479)
IGFBP-3 (3486)
Serpin E1 (5054)
Thrombospondin 1 (7057)
Prostate cancer 2.0 ˆ 10´3
IGF1 (3479)
IGF2 (3481)
PDGF AA (5154)
PDGFRA (5156)
Cytokine-cytokine
receptor interaction 6.0 ˆ 10
´3
PDGF AA (5154)
PDGFRA (5156)
IL-17 (3506)
IL-17RA (23,765)
MCP-1 (6347)
Glioma 1.4 ˆ 10´2
IGF1 (3479)
PDGF AA (5154)
PDGFRA (5156)
Melanoma 1.8 ˆ 10´2
IGF1 (3479)
PDGF AA (5154)
PDGFRA (5156)
Focal adhesion 1.9 ˆ 10´2
IGF1 (3479)
PDGF AA (5154)
PDGFRA (5156)
Thrombospondin 1 (7057)
hsubMSC, Undifferentiated-High Abundance Analytes
Associated KEGG-Pathway p-Value Analytes Involved(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 6.0 ˆ 10
´5
IL-17 (3506)
IL-17RA (23,765)
MCP-1 (6347)
ENA-78 (6374)
IL-8 (3576)
CXCR1 (3577)
CXCR2 (3579)
LRP5 (4041)
LRP6 (4040)
CXCR1 (3577)
CXCR2 (3579)
PLAU (5328)
PLAT (5327)
PLG (5340)
CCR2 (1231)
IL-17RA (23,765)
RELA (5970)
Chemokine signalling
pathway 1.4 ˆ 10
´4
MCP-1 (6347)
ENA-78 (6374)
IL-8 (3576)
CXCR1 (3577)
CXCR2 (3579)
RELA (5970)
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Table 3. Cont.
Epithelial cell signalling in
Helicobacter pylori infection 9.3 ˆ 10
´4
IL-8 (3576)
CXCR1 (3577)
CXCR2 (3579)
RELA (5970)
Complement and
coagulation cascades 9.7 ˆ 10
´4
PLAU (5328)
PLAT (5327)
PLG (5340)
Serpin E1 (5054)
NOD-like receptor
signalling pathway 1.4 ˆ 10
´2
MCP-1 (6347)
RELA (5970)
IL-8 (3576)
Wnt signalling pathway 7.1 ˆ 10´2
Dkk-1 (22,943)
LRP5 (4041)
LRP6 (4040)
Table 4. Pathway analysis by the David database of high abundance analytes secreted by hepatocytic
differentiated hbmMSC and hsubMSC and 10 potential interaction partners as predicted by the STRING
database (input of analytes as summarised in Tables S3 and S4). Associated KEGG-pathways with
p-values of significance as well as analytes involved are shown.
hbmMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Involved Analytes(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 1.8 ˆ 10
´16
MCP-1 (6347)
MIP-3 α (6364)
RANTES (6352)
MCP-3 (6354)
CCR5 (1234)
Gro-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
M-CSF (1435)
GM-CSF (1437)
CSF2RA (1438)
FLT1 (2321)
IL-17 (3506)
IL-6 (3569)
IL-6R (3570)
IL-6ST (3572)
IL-8 (3576)
KDR (3791)
VEGF A (7422)
KDR (3791)
FLT1 (2321)
IGF1 (3479)
IL-6R (3570)
LRP6 (4040)
CCR5 (1234)
CSF2RA (1438)
IL-6ST (3572)
NRP1 (8829)
IGF2 (3481)
Chemokine signalling
pathway 8.4 ˆ 10
´6
MCP-1 (6347)
MIP-3 α (6364)
RANTES (6352)
MCP-3 (6354)
CCR5 (1234)
Gro-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-8 (3576)
NOD-like receptor
signalling pathway 2.6 ˆ 10
´5
MCP-1 (6347)
RANTES (6352)
MCP-3 (6354)
Gro-α (2919)
IL-6 (3569)
IL-8 (3576)
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Table 4. Cont.
hbmMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Involved Analytes(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Hematopoietic cell lineage 1.5 ˆ 10´3
M-CSF (1435)
GM-CSF (1437)
CSF2RA (1438)
IL-6 (3569)
IL-6R (3570)
p53 signalling pathway 7.2 ˆ 10´3
IGF1 (3479)
IFGBP3 (3486)
Serpin E1 (5054)
Trombospondin 1 (7057)
JAK-STAT signalling
pathway 9.6 ˆ 10
´3
GM-CSF (1437)
CSF2RA (1438)
IL-6 (3569)
IL-6R (3570)
IL-6ST (3572)
Bladder cancer 2.5 ˆ 10´2
IL-8 (3576)
Thrombospondin-1 (7057)
VEGF A (7422)
Focal adhesion 9.7 ˆ 10´2
KDR (3791)
FLT1 (2321)
Thrombospondin 1 (7057)
VEGF A (7422)
mTOR signalling pathway 3.7 ˆ 10´2
IGF1 (3479)
IGF2 (3481)
VEGF A (7422)
Pathways in cancer 4.1 ˆ 10´2
CFS2RA (1438)
FGF-19 (9965)
IGF1 (3479)
IL-6 (3569)
IL-8 (3576)
VEGF A (7422)
Epithelial cell signalling in
Helicobacter pylori infection 6.0 ˆ 10
´2
RANTES (6352)
Gro-α (2919)
IL-8 (3576)
Complement and
coagulation cascades 6.2 ˆ 10
´2
uPAR (5329)
Complement factor D (1675)
Serpin E1 (5054)
hsubMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Analytes Involved(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Cytokine-cytokine
receptor interaction 1.3 ˆ 10
´8
KDR (3791)
FLT1 (2321)
MCP-1 (6347)
Gro-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-8 (3576)
IL-17A (3605)
CXCR2 (3579)
CXCR4 (7852)
Leptin (3952)
VEGF A (7422)
KDR (3791)
FLT1 (2321)
IGF-1 (3479)
LRP6 (4040)
IGF-2 (3481)
NRP1 (8829)
PLAU (5328)
CXCR4 (7852)
HIF1A (3091)
CXCR2 (3579)
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Table 4. Cont.
hbmMSC, Hepatocytic Differentiated—High Abundance Analytes
Associated KEGG-Pathway p-Value Involved Analytes(Entrez Gene ID)
Predicted Genes
(Entrez Gene ID)
Chemokine signalling
pathway 2.3 ˆ 10
´4
MCP-1 (6347)
MIP-3 α (6364)
Gro-α (2919)
SDF-1 α (6387)
ENA-78 (6374)
IL-8 (3576)
CXCR2 (3579)
CXCR4 (7852)
mTOR signalling pathway 2.0 ˆ 10´3
HIF1A (3091)
IGF1 (3479)
IGF2 (3481)
VEGF A (7422)
p53 signalling pathway 4.3 ˆ 10´3
IGF-1 (3479)
IGFBP-3 (3486)
Serpin E1 (5054)
Thrombospondin 1 (7057)
Complement and
coagulation cascades 4.4 ˆ 10
´3
uPAR (5329)
PLAU (5328)
Complement factor D (1675)
Serpin E1 (5054)
Focal adhesion 1.6 ˆ 10´2
KDR (3791)
FLT1 (2321)
IGF-1 (3479)
Thrombospondin 1 (7057)
VEGF A (7422)
Bladder cancer 1.8 ˆ 10´2
IL-8 (3576)
Thrombospondin 1 (7057)
VEGF A (7422)
NOD-like receptor
signalling pathway 3.7 ˆ 10
´2
MCP-1 (6347)
Gro-α (2919)
IL-8 (3576)
Epithel cell signalling in
Heliobacter pylori infection 4.3 ˆ 10
´2
Gro-α (2919)
IL-8 (3476)
CXCR2 (3579)
Endocytosis 6.0 ˆ 10´2
CXCR4 (7852)
IL-8 (3576)
FLT1 (2321)
KDR (3791)
Pathways in cancer 7.4 ˆ 10´2
IGF-1 (3479)
HIF1A (3091)
FGFR2 (2263)
FGF-7 (2252)
FGF-19 (9965)
IL-6 (3569)
IL-8 (3576)
VEGF A (7422)
Using the PathCards pathway unification database, the TGF-β Pathway Super Path was identified
involving 686 genes in part regulated by factors secreted by hepatocytic differentiated hsubMSC and
hbmMSC at low, medium and high abundance (PathCards pathway unification database), (Table 5).
The TGF-beta pathway consists of a pathway network including the SOCS pathway, regulation of the
eIF4 and p70S6K pathways, the TGF-β, JAK-STAT, JNK and MAPK pathways.
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Table 5. Analytes secreted by hepatocytic differentiated hbm- and hsub-MSC in association with the
TGF-β Pathway Super Path as identified by the PathCards pathway unification database.
TGF-β Pathway-Related Analytes
Cell Type Low Abundance Medium Abundance High Abundance
hbmMSC, hepatocytic
differentiated
BAFF
BDNF
IL-1α
IL-1β
IL-2
IL-3
IL-10
IL-13
IL15
IL-16
IL-19
IL-24
MIP-1α/MIP-1β
MIP-3β
PDGF-AA
TARC
TGFα
Angiopoetin-2
FGF basic
FGF-7
IL-4
IL-11
IL-22
Angiopoetin-1
FGF-19
GDF-15
IL-17
IL-6
IL-8
MCP-1
MCP-3
MIP-3α
RANTES
SDF-1α
hsubMSC, hepatocytic
differentiated
Angiopoetin-1
Angiopoetin-2
BAFF
FGF basic
IL-1α
IL-1β
IL-10
IL-11
IL-24
MCP-3
PDGF-AA
RANTES
TARC
BDNF
FGF-7
IL-4
IL-6
IL-22
MIP-3α
FGF-19
GDF-15
IL-8
IL-17A
MCP-1
SDF-1α
3. Discussion
3.1. Paracrine Mechanisms in Liver Repair
MSC have been isolated from a wide variety of organisms and tissues and have been classified
based on their multipotent differentiation capacity, ability to adhere to plastic substrata and expression
of a specific set of mesenchymal surface markers [39,40]. Even if bona fide compatible with these criteria,
it must be anticipated that cells from different sources may share similar but not identical functional
features [41,42]. We corroborated this assumption by showing that MSC from human bone marrow
and different sources of adipose tissue displayed the same surface marker profile, which changed
after hepatocytic differentiation indicating a change in biological properties. According to their organ
resident status, MSC are believed to support tissue regeneration by functional tissue replacement
through differentiation into cells of the host organ/tissue or by secretion of paracrine factors, providing
trophic support for self-regeneration of the tissue they reside in [7,43]. It is known that MSC secrete
a multitude of soluble factors mediating pleiotropic actions such as immune-modulation, tissue
regeneration or angiogenesis and others [26,27,44,45]. In summary, these features of MSC also seem to
mediate the beneficial impact on both acute and chronic liver diseases. It was initially believed that
the amelioration of liver damage by the stem cells required integration and functional specialization
on the site of integration [46]. However, it became obvious, that paracrine factors, which have
not been identified unequivocally so far, were the major principle of action [21–23,47]. Therefore,
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the trophic effect of MSC on the liver can probably be attributable to paracrine anti-inflammatory,
immune-modulatory, anti-apoptotic and pro-proliferative actions augmenting self-regeneration of the
liver [48,49].
Here, we compared secretion of factors from bone marrow- and adipose tissue-derived MSC
before and after hepatocytic differentiation. MSC from different sources secreted a similar albeit
not identical pattern of factors, corroborating previous results from bone marrow- and umbilical
cord blood-derived MSC [50]. Pathway analyses of highly expressed factors revealed a strong
correlation with processes engaged in liver regeneration such as cytokine/chemokine pathways
regulating hepatic and extrahepatic immune reactions as well as inflammation, growth factor pathways
regulating initiation and termination of hepatocyte proliferation, factors involved in the complement
and coagulation cascade as well as in epithelial-to-mesenchymal transition (EMT) and angiogenesis,
all required for morphogenic and parenchymal remodelling after chronic injury like fibrosis and
cirrhosis. Finally, the association with the TGF-β pathway, which in the liver is involved in hepatocyte
proliferation and differentiation after acute liver damage as well as in cell death and fibrotic tissue
remodelling in the pathogenesis of chronic liver diseases [51], indicates that MSC-derived molecules
may extensively interfere with both parenchymal and non-parenchymal tissue homeostasis in the liver.
3.2. Functional Relevance
IL-17A, MCP-1, Pentraxin 3, Serpin E1 and Thrompospondin-1 were mainly expressed by both
undifferentiated bone marrow- and adipose tissue-derived MSC. IL-17A, a pro-inflammatory cytokine
produced by Th17 and innate immune cells, protects the host from extracellular pathogens by the
recruitment of immune cells like neutrophils. While poorly active on its own, IL-17 synergises
with IL-1β, IL-22, IFNγ and GM-CSF supporting the host defence reaction by the augmentation of
pro-inflammatory cytokines such as IL-6 and IL-8 [52]. A similar autocrine mechanism may underlie
the increase in expression of these factors after hepatocytic differentiation of MSC as observed here.
Pentraxin 3 was expressed at high abundance under all conditions tested here (Figure 2).
As a member of the long pentraxin family, it plays an essential part in the regulation of innate immunity,
inflammation, complement activation and matrix deposition [53]. Also, Pentraxin 3 deficiency was
associated with an enhanced inflammatory response and tissue damage [53], thus corroborating its
essential role in tissue regeneration. As a key component of the innate immunity, Pentraxin 3 activated
the downstream TLR4-MyD88 pathway during urinary tract infection [54]. The potential role of
Pentraxin 3 in liver regeneration might be contributed to its interaction with FGF family members like
FGF-2. Pentraxin 3 inhibited FGF-2-dependent endothelial cell proliferation and neovascularisation
by the sequestration of FGF-2 [55]. The crosstalk with growth factor signaling, namely HGF and
EGF, thus might link Pentraxin 3 functionally to the TGF-β pathway, which is the key player in
liver morphogenesis and liver regeneration after partial hepatectomy, regulating both hepatocyte
proliferation and growth termination [51,56]. Substantiating the impact of MSC on innate immune
regulation, MCP-1 was mainly abundant in supernatants of undifferentiated MSC. In the injured
liver, MCP-1 might originate from liver-resident macrophages, the Kupffer cells, to attract monocytes
via the chemokine receptor CCR2. Normally involved in tissue remodelling and disease regression,
inflammatory macrophages, however, might promote disease progression [57]. In line with its role in
tissue remodelling as discussed above, soluble urokinase-type plasminogen activator receptor (uPAR)
regulated the activity of MCP-1 and RANTES (CCL5) [58], which besides others regulate pattern
recognition via NOD-like receptor signalling, thus coordinating innate immune activity with tissue
homeostasis. The potential role of differentiated MSC in tissue remodelling is substantiated by the
increase in CD54 (ICAM-1) expression (Figure 1). On human renal fibroblasts, ICAM-1 increased after
activation by cross-linking the synthesis of RANTES and IL-8 [59], the latter acting as a chemo-attractant
for granulocytes and is also abundant after differentiation of hbm- and hsubMSC as shown here.
Moreover, on liver cells, ICAM-1 allows macrophages recruited by MCP-1 to adhere via the LFA-1
ligand [60]. This might also substantiate that the MSC differentiated into the hepatocytic lineage,
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which is also corroborated by the decrease of CD166 expressed as mesenchymal stem cell marker on
liver fibroblasts [61].
Serpin E1, also known as plasminogen activator inhibitor-1 (PAI-1), is part of the fibrolytic
system, and as such contributes to tissue remodelling after partial hepatectomy [62], angiogenesis
and tumour progression [63]. It is a major acute phase reactant [64] and its expression is strongly
enhanced by inflammatory stimuli [65]. In rat hepatocytes, the artificial glucocorticoid dexamethasone
increased TGFβ-induced Serpin E1 expression [64] connecting Serpin E1 with the regulation of
epithelial-to-mesenchymal transition (EMT) promoted by TGF-β [66]. Insulin and dexamethasone,
two ingredients of the medium used in this study, are strong inducers of Serpin E1 expression.
Insulin increased Serpin E1 expression via the MAPK or the phosphoinositide-3-kinase–protein kinase
B (PI3K/PKB) pathway and indirectly via HIF1α [64]. Serpin E1 and uPAR, expressed by both bone
marrow- and adipose tissue-derived MSC, are targets of HIF1α. While HIF1α promotes upregulation
of growth factors like FGF-2 and HGF, HIF2α induces VEGFA, all of which are known to support
wound healing [58]. In addition, Serpin E1 was reported to stimulate cell migration by the low
density lipoprotein receptor-related protein 1 (LRP1)-dependent activation of the Wnt/β-catenin and
ERK1/2-MAPK pathways [63]. In line with the impact of MSC on tissue remodelling after chronic
liver disease, the inhibitor of Wnt-signalling, Dickkopf-1 (Dkk-1), highly abundant in supernatants of
undifferentiated MSC, might foster resolution of fibrosis by the down-regulation of hepatic stellate
cell activation [67]. Thus, Serpin E1 secreted by MSC seems to contribute to tissue remodelling and
morphogenesis, thereby promoting liver regeneration after injury. In contrast, Thrombospondin-1,
highly expressed by undifferentiated hsub- and hbmMSC, has been shown to suppress VEGF activity
and hepatocyte growth through TGF-β-dependent mechanisms [31,68], thus antagonising liver
regeneration. Indeed, platelet-derived α-granules contained both Thrombospondin-1 and VEGF,
and human data demonstrated that high Thrombospondin-1 and low VEGF were predictors of liver
dysfunction after resection [69].
Hepatocytic differentiation of both hsubMSC and hbmMSC further increased secretion of the
factors as discussed above and moreover a wide variety of proteins, which might interfere with different
pathways involved in the maintenance of liver architectural and functional homeostasis. To discuss
a selection, VEGF as well as angiopoietins 1 and 2 are important promoters of liver regeneration [30].
Platelet-derived growth factor AA (PDGF-AA), albeit expressed in low abundance, is mainly produced
by plateletsin vivo. Its hepatotropic properties have been corroborated by the transplantation of
platelets improving liver regeneration after resection in rats [70] and in patients after living donor
transplantation [71]. FGF-19 might stimulate insulin-dependent pathways regulating hepatic protein
and glycogen metabolism [72]. The neurotrophin BDNF mediated cell survival and repair in the brain
after ischemia [73]. It might act similarly in the liver since it has been shown that rat and human hepatic
stellate cells and hepatocytes expressed BDNF and other neurotrophins involved in the pathogenesis
of liver diseases [74]. The expression of chitinase 3-like 1 by hepatic stellate cells, which was positively
associated with cell survival and negatively with liver fibrosis [75], might be enhanced by MSC-derived
IL-6. Complement factor D, the rate limiting step of the alternative pathway of complement activation,
may act as an adipokine, thus linking tissue homeostasis and metabolic regulation in chronic liver
diseases like non-alcoholic steatohepatitis (NASH) [76,77]. Sex hormone-binding globulin (SHBG),
mainly secreted by hepatocytic differentiated hsubMSC, is a liver-derived plasma protein, whose low
levels were associated with non-alcoholic fatty liver disease (NAFLD) [78] and insulin resistance [79].
Stromal cell-derived factor 1 (SDF-1), stimulating homing to and differentiation of MSC at the site
of injury [80] via its receptor C-X-C chemokine receptor type 4 (CXCR4), was highly expressed after
hepatocytic differentiation, which might be due to the autocrine activation by Macrophage migration
inhibitory factor (MIF) [81], also expressed in high levels after differentiation.
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4. Experimental Section
4.1. Human Material
Human bone marrow was obtained during elective knee or hip joint surgery, human adipose
tissue (subcutaneous, visceral and mesenteric) during abdominal surgery after receiving the patients´
written consent as approved by the Institutional Ethics Review Board Leipzig (file No. 282-11-22082011
and 282-10-04102010).
4.2. Mesenchymal Stem Cell Isolation, Propagation and Hepatocytic Differentiation
Human bone marrow and adipose tissue were collected in high glucose Dulbecco’s Modified
Eagle’s medium (DMEM) (Gibco, Paisley, UK). Adipose tissue was further cut into pieces and tissues
of both origins were subsequently incubated for 25 min at 37 ˝C with collagenase (0.2 unit/mL,
NB4G, Serva, Heidelberg, Germany). Digestion was stopped by addition of 5 mL fetal bovine serum
(Gibco, Paisley, UK) followed by several washing steps in phosphate-buffered saline (PBS). MSC were
enriched by density gradient centrifugation, propagated and cryopreserved essentially as described.
Upon thawing, cells were seeded (400 cells/cm2) onto human fibronectin-coated culture dishes in
growth medium and cultured until reaching a confluence of 80%–90% (7–10 days). These cells were
used for analyses of undifferentiated MSC. Hepatocytic differentiation was initiated by continuing
culture with 51-Azacytidine for another 24 h. Thereafter, the medium was changed and culture
proceeded in human hepatocyte medium supplemented with 2% fetal calf serum, HGF and EGF
routinely until day 16 of hepatocytic differentiation as described in detail in [19]. Analyses were
performed with non-pooled and non-passaged stocks of MSC from the number of donors as given in
the legends to the figures.
4.3. Microscopic Documentation of Morphology
Morphology of the undifferentiated MSC from different origins was documented using the phase
contrast microscope Primo Vert with the Zen software (Zeiss, Jena, Germany).
4.4. Flow Cytometry
After correction for the IgG isotype control, surface marker profiles of undifferentiated and
hepatocytic differentiated human bone marrow- and adipose tissue-derived MSC were captured by
flow cytometry using the LSR II FACS Diva 8.0.1 software (Becton Dickinson Bioscience, San Jose,
CA, USA). Data were analysed by Kathrin Jäger and Andreas Lösche at the Core Unit Fluorescence
Technologies, Interdisciplinary Centre for Clinical Research (IZKF), University Leipzig. Experimental details
are described elsewhere [18,19,82] and antibodies used are listed in Table S6. Dead cells were excluded
from the measurements by propidium iodide staining. For the sake of comparability with our previous
studies, differentiation was continued until day 21 of hepatocytic differentiation [18,19]. Data shown
are means of 3–5 analyses with cells from different donors.
4.5. Sample Preparation and Proteome Profiler Antibody Array
Proteome analyses were performed with bone marrow- and subcutaneous adipose tissue-derived
MSC from three different donors each. Undifferentiated cells were cultured in growth medium
supplemented with 15% inactivated fetal bovine serum until 65% confluence. After washing with
PBS for three times, culture was continued in growth medium without serum addition. After another
four days without medium change, supernatants were collected for analyses (cell numbers—hbmMSC:
350,000 ˘ 24,000, hsubMSC: 450,000 ˘ 80,500, p = 0.22). Hepatocytic differentiated MSC were grown
for 12 days in human hepatocyte medium as described above. Then the cells were washed three times
with PBS and culture continued for another 4 days in serum-free human hepatocyte medium before
the supernatants were collected for analyses (cell numbers—hbmMSC: 470,000 ˘ 40,000, hsubMSC:
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880,000 ˘ 78,000, p = 0.0002). To assess background reactions, negative controls without cells were run
under both culture settings.
Supernatants were centrifuged for 5 min (4 ˝C, 1.5ˆ g) and 300 µL of each sample were incubated
overnight with binding buffer according to the manufacturer’s instructions for use of the Proteome
Profiler™ Human XL Cytokine Array Kit (R&D Systems, Minneapolis, MN, USA), which detects
102 proteins as listed in Supporting Information Table 2. After washing, membranes were incubated
with the detection cocktail for 1 h, followed by washing steps, incubation with streptavidin-conjugated
horseradish peroxidase (HRP, R&D Systems, Minnesota, MN, USA) for 30 min, another washing steps,
and finally the incubation with the chemiluminescence reagent for 1 min. Abbreviations of proteins as
analysed by the arrays are listed under Table S6.
4.6. Array Analysis and Bioinformatics
For bioinformatics analyses, labelled proteins were visualized by the Micro Chemi 4.2 using the
gel capture software (Biostep, Burkhardtsdorf, Germany). Serial pictures with an exposure time of
9 min were quantified using Image J 1.46 (NIH, Bethesda, MD, USA) and corrected for background
signals of the negative controls. Mean pixel density of reference spots was set to 100, to which all
other values given are relative. During hepatocytic differentiation cell number increased as described
above due to the presence of HGF and EGF. Therefore, results were corrected for the number of
hbmMSC and hsubMSC before and after hepatocytic differentiation. Accounting for the fact that the
medium contained some ingredient proteins cross-reacting with the array, proteins with a relative
mean pixel density below 5 were categorized as “not abundant” (unspecific background signals),
between 5 and 15 as “low abundant”, between 15 and 30 as “medium abundant” and above 30 as “high
abundant”. Predicted interactions of the cytokine network of high abundance analytes (entered in the
ENTREZ GENE ID format) as well as the association with another 10 predicted potential interaction
partners were visualised using the online STRING database platform (http://string-db.org/) [83],
which was also used for predicted pathway analysis of all abundant analytes. Predicted pathway
analysis of high abundant analytes was performed by the DAVID Bioinformatics Resources 6.7 database
(https://david.ncifcrf.gov/) [84,85] and associated with KEGG-pathways. The TGF-β Pathway Super
Path and corresponding genes were assessed by using the PathCards pathway unification database
(http://pathcards.genecards.org/) [86].
4.7. Statistics
Experiments were repeated at least three times. Results are shown as means ˘ standard error of
the mean. If not otherwise mentioned, Student’s t-test was used to confirm significant differences at
the level of p as indicated in the legends to the figures.
5. Conclusions
The compilation of factors produced by human MSC from different tissue sources demonstrated
that the manipulation of the cells like hepatocytic differentiation dramatically changed the pattern
of the secreted proteins, both qualitatively and quantitatively. The comprehensive analysis of
factors and their targeted pathways unravelled a variety of hepatotropic networks involved in the
regulation of tissue and functional homeostasis during the pathogenesis and regression of liver diseases.
Pathways addressed by both undifferentiated MSC and hepatocytic differentiated MSC comprised
the innate and adaptive immunity, proliferation and apoptosis, liver regeneration, the complement
and coagulation pathway as well as cytokine and chemokine pathways. It is evident from our study
that these pathways and the respective factors secreted by human MSC regulating these pathways are
tentatively involved in hepatic repair after injury, but may also contribute to disease progression. It is
hence of utmost importance before clinical applications, to determine the pattern of factors secreted by
a specific MSC population, both native and after manipulation, in order to delineate and predict the
potential impact on liver diseases. It is also evident that the pattern of factors secreted by MSC may be
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impacted by the specific liver disease, which is targeted by MSC therapy. It must be anticipated, that
host- and donor MSC-derived paracrine and autocrine loops imprint the secretory pattern of MSC,
which may result in either disease aggravation or amelioration [87]. Even if possible, the breakdown
of MSC action to single molecular pathways to be addressed as therapeutic targets seems neither
reasonable nor reliable for the use of MSC in treating liver diseases, since the pleiotropic actions of
MSC rely on the intersection with disease-tailored signals and networks generated by the diseased
host liver. Knowledge of these intersections as provided by our study will facilitate the individualised
application and the prediction of the most assumable success of MSC therapy for liver diseases.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/7/1099/s1.
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